Cytokinetics (CYTK) Stock Price, Quote & News

Company Profile

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a pot...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 624 3000

Website: www.cytokinetics.com

Address:

350 Oyster Point Boulevard, South San Francisco, United States

Quantumup Sep. 11 at 11:42 AM

Cantor reiterated an Overweight rating on $CYTK after its fireside chat w/ mgmt. $EWTX $BMY TECX TENC AZN NVO BAYRY Here's what Cantor said in its note to investors: https://x.com/Quantumup1/status/2098376353619870023?s=20

0 · Reply

biochirp Sep. 9 at 1:38 AM

$CYTK should be 85+

0 · Reply

BiotechButterflies Sep. 8 at 7:53 PM

$NVS ... so.. maybe they'll have another shot at $CYTK to try to beef up the near term Cardiovascular franchise.... any other obvious M&A targets....maybe $NAMS who clearly would be another great option...

2 · Reply

SM07 Sep. 8 at 1:57 PM

$CYTK Usual morning pump followed by the afternoon dump

0 · Reply

forprofit12 Sep. 8 at 1:28 PM

$CYTK near term buyout possible. All the best

0 · Reply

biochirp Sep. 7 at 4:00 PM

$CYTK 3 CV drug failures the past couple weeks, is it time?

0 · Reply

Quantumup Sep. 1 at 10:11 AM

Truist on $CYTK (Buy; $112) said -- We reiterate our Buy for CYTK following detailed ACACIA analyses at ESC this past weekend. $EWTX $BMY TECX TENX AZN NVO BAYRY Truist added—Despite ACACIA's imbalance in heart failure (4.7% vs. 1.2% pbo), we see a sizable and under-appreciated opportunity with Myqorzo in HCM (we model $5.8B in WW peak rev, 2036E). KOL checks highlight HF as a known side effect of CMIS, ACACIA had no afi-related deaths, improved HF rates with real-world-like use (FOREST-HCM). We believe Myqorzo will likely become the first approved therapy for nHCM (possibly with different REMS vs. oHCM) making it the only approved therapy for all of HCM, with potential to promote its use case over oHCM-only CMIs. We reiterate our Buy rating and $112 PT.

0 · Reply

buddyopalosam Aug. 31 at 4:46 PM

$CYTK ok i am out. This seems like. Its headed to tne 50's.

0 · Reply

JuniorTrader83 Aug. 31 at 4:29 PM

$CYTK buyers incoming 🚀

1 · Reply

macrossluvsrobotech Aug. 31 at 3:29 PM

$LXRX Cardio Landscape NEWS TODAY in Plain English! 🫀📊 $LLY latest Cardio News Today , how it affects $LXRX Cardio treatment: 1. LLY MOUNJARO: FDA approved to cut MACE (heart attacks/strokes). Trial was vs Trulicity ($LLY's older GLP-1) showing HR 0.92 (8% risk cut). Mounjaro targets plaque; INPEFA clears fluid in heart failure. They don't compete—doctors use both! $CYTK recent news, how it affects $LXRX 2. CYTK SAFETY FLAW: Aficamten (myosin inhibitor) turns down heart squeeze. Symptom gains were tiny (KCCQ +3.0), but 10.5% suffered a dangerous heart pump drop (LVEF <50% vs 0.8% placebo). Pump tax! $LXRX’s SONATA-HCM treats stiff hearts WITHOUT weakening the pump. 3. LXRX NEW DATA TODAY: Analyzed low blood pressure patients (top number SBP <110). Sotagliflozin delivered HR 0.56 = 44% reduction in CV death & HF events (p=0.03) with ZERO excess kidney damage or fainting vs placebo. Proves safety in fragile patients! $NVO $VRTS PR: https://lexiconpharma.gcs-web.com/news-releases/news-release-details/lexicon-announces-new-post-hoc-soloist-whf-analysis

0 · Reply

Cytokinetics Transcript: Citigroup’s Biopharma Back to School Summit 2026

Sep 9, 2026, 7:00 AM EDT - 4 days ago

Cytokinetics Slides: Corporate presentation

Sep 2, 2026, 4:00 PM EDT - 10 days ago

Cytokinetics to Participate in September Investor Conferences

2026-08-30T19:35:05.000Z - 13 days ago

Cytokinetics announces results from ACACIA-HCM, MAPLE-HCM

Aug 29, 2026, 10:30 AM EDT - 15 days ago

Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026

Aug 28, 2026, 8:00 AM EDT - 16 days ago

Cytokinetics Transcript: Investor update

Aug 28, 2026, 8:00 AM EDT - 16 days ago

Cytokinetics Press release: Investor update

2026-08-28T10:05:17.000Z - 16 days ago

Cytokinetics reports ACACIA-HCM trial met both primary endpoints

Aug 28, 2026, 5:52 AM EDT - 16 days ago

Cytokinetics eyes expanded use of heart drug after promising late-stage data

Aug 28, 2026, 5:45 AM EDT - 16 days ago

Cytokinetics Announces Positive Results from ACACIA-HCM Presented in Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 and Published in The New England Journal of Medicine

Aug 20, 2026, 7:30 AM EDT - 24 days ago

Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026

Aug 18, 2026, 4:00 PM EDT - 25 days ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-08-17T08:20:15.000Z - 27 days ago

Cytokinetics price target raised to $110 from $95 at Barclays

2026-08-17T07:59:46.000Z - 27 days ago

Cytokinetics price target raised to $103 from $97 at JPMorgan

2026-08-10T14:15:46.000Z - 4 weeks ago

Cytokinetics price target raised to $112 from $106 at Truist

2026-08-07T15:50:29.000Z - 5 weeks ago

Cytokinetics price target raised to $85 from $83 at BofA

2026-08-07T13:38:31.000Z - 5 weeks ago

Cytokinetics price target raised to $112 from $102 at Needham

2026-08-07T12:15:42.000Z - 5 weeks ago

Cytokinetics price target lowered to $112 from $117 at RBC Capital

2026-08-07T10:17:20.000Z - 5 weeks ago

Cytokinetics price target raised to $110 from $105 at Citizens

Aug 6, 2026, 4:30 PM EDT - 5 weeks ago

Cytokinetics Earnings Call Transcript: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 5 weeks ago

Cytokinetics Earnings release: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 5 weeks ago

Cytokinetics Quarterly report: Q2 2026

2026-08-06T20:06:34.000Z - 5 weeks ago

Cytokinetics reports Q2 EPS ($1.50), consensus ($1.60)

Jul 30, 2026, 6:48 AM EDT - 6 weeks ago

Cytokinetics wins UK approval, NICE backing for heart disease drug

2026-07-30T10:25:52.000Z - 6 weeks ago

Cytokinetics announces MHRA authorization for Myqorzo

Jul 30, 2026, 6:20 AM EDT - 6 weeks ago

Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales

Jul 23, 2026, 4:00 PM EDT - 7 weeks ago

Cytokinetics to Announce Second Quarter Results on August 6, 2026

2026-07-07T11:36:10.000Z - 2 months ago

Cytokinetics price target lowered to $117 from $119 at RBC Capital

Jul 7, 2026, 7:30 AM EDT - 2 months ago

Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026

2026-06-29T10:20:13.000Z - 2 months ago

Cytokinetics upgraded to Buy from Neutral at UBS

2026-06-24T11:06:08.000Z - 2 months ago

Cytokinetics price target raised to $118 from $100 at Mizuho

Jun 8, 2026, 9:20 AM EDT - 3 months ago

Cytokinetics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 7:30 AM EDT - 3 months ago

Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program

Jun 3, 2026, 8:10 AM EDT - 3 months ago

Cytokinetics Transcript: Jefferies Global Healthcare Conference 2026

2026-06-01T14:24:49.000Z - 3 months ago

Cytokinetics launches Myqorzo in Germany

Jun 1, 2026, 7:30 AM EDT - 3 months ago

Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany

May 27, 2026, 4:00 PM EDT - 3 months ago

Cytokinetics to Participate in June Investor Conferences

May 27, 2026, 1:00 PM EDT - 3 months ago

Cytokinetics Transcript: AGM 2026

May 27, 2026, 7:00 AM EDT - 3 months ago

Cytokinetics Slides: Corporate presentation

May 20, 2026, 4:00 PM EDT - 3 months ago

Cytokinetics to Hold Annual Meeting of Stockholders

May 19, 2026, 3:35 PM EDT - 3 months ago

Cytokinetics Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 19, 2026, 7:00 AM EDT - 3 months ago

Cytokinetics Slides: Corporate presentation

2026-05-18T20:22:58.000Z - 3 months ago

Cytokinetics initiated with a Buy, named a top pick at Citi

May 18, 2026, 4:00 PM EDT - 3 months ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

May 14, 2026, 7:30 AM EDT - 4 months ago

Cytokinetics to Host Annual Symposium on Contemporary Landscapes in Muscle Biology (CLIMB)

May 12, 2026, 4:00 PM EDT - 4 months ago

Cytokinetics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

May 11, 2026, 10:06 AM EDT - 4 months ago

Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026

May 8, 2026, 10:51 AM EDT - 4 months ago

Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $805 Million

May 6, 2026, 11:00 PM EDT - 4 months ago

Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock

May 5, 2026, 4:30 PM EDT - 4 months ago

Cytokinetics Earnings Call Transcript: Q1 2026

May 5, 2026, 4:30 PM EDT - 4 months ago

Cytokinetics Quarterly report: Q1 2026

May 5, 2026, 4:30 PM EDT - 4 months ago

Cytokinetics Earnings release: Q1 2026

May 5, 2026, 4:30 PM EDT - 4 months ago

Cytokinetics Slides: Q1 2026

May 5, 2026, 4:15 PM EDT - 4 months ago

Cytokinetics Announces Proposed Public Offering of Common Stock

May 5, 2026, 4:05 PM EDT - 4 months ago

Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update

May 5, 2026, 8:00 AM EDT - 4 months ago

Cytokinetics Transcript: Study result

May 5, 2026, 8:00 AM EDT - 4 months ago

Cytokinetics Press release: Study result

May 5, 2026, 8:00 AM EDT - 4 months ago

Cytokinetics Slides: Study result

May 5, 2026, 7:35 AM EDT - 4 months ago

Cytokinetics heart disease drug meets main goals in late-stage study

May 5, 2026, 7:30 AM EDT - 4 months ago

Cytokinetics Announces Positive Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy

May 4, 2026, 4:00 PM EDT - 4 months ago

Cytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026

Apr 28, 2026, 7:30 AM EDT - 4 months ago

Cytokinetics Announces Nine Upcoming Presentations at the European Society of Cardiology Heart Failure 2026 Congress

Apr 21, 2026, 4:00 PM EDT - 4 months ago

Cytokinetics to Announce First Quarter Results on May 5, 2026

Apr 17, 2026, 8:00 AM EDT - 4 months ago

Cytokinetics Proxy statement: Proxy filing

Apr 13, 2026, 1:30 PM EDT - 5 months ago

Cytokinetics Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 6, 2026, 4:00 PM EDT - 5 months ago

Cytokinetics to Participate in the 25th Annual Needham Virtual Healthcare Conference

Mar 16, 2026, 8:00 AM EDT - 6 months ago

Cytokinetics Announces Four Presentations at the American College of Cardiology Annual Scientific Session & Expo

Mar 11, 2026, 12:30 PM EDT - 6 months ago

Cytokinetics Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 10, 2026, 9:00 AM EDT - 6 months ago

Cytokinetics Transcript: The Citizens Life Sciences Conference 2026

Mar 9, 2026, 9:20 AM EDT - 6 months ago

Cytokinetics Transcript: Leerink Global Healthcare Conference 2026

Mar 5, 2026, 7:00 AM EST - 6 months ago

Cytokinetics Slides: Corporate presentation

Mar 2, 2026, 4:00 PM EST - 6 months ago

Cytokinetics to Participate in March Investor Conferences

Feb 24, 2026, 4:30 PM EST - 6 months ago

Cytokinetics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 4:30 PM EST - 6 months ago

Cytokinetics Annual report: Q4 2025

Feb 24, 2026, 4:30 PM EST - 6 months ago

Cytokinetics Earnings release: Q4 2025

Feb 24, 2026, 4:30 PM EST - 6 months ago

Cytokinetics Annual report: Q4 2025

Feb 24, 2026, 4:00 PM EST - 6 months ago

Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update

Feb 17, 2026, 7:30 AM EST - 6 months ago

Cytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Feb 12, 2026, 4:00 PM EST - 7 months ago

Cytokinetics to Announce Fourth Quarter Results on February 24, 2026

Feb 9, 2026, 7:30 AM EST - 7 months ago

Cytokinetics Announces Recipients of Its Eighth Annual Communications Grant Program

Jan 27, 2026, 7:30 AM EST - 7 months ago

Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

Jan 22, 2026, 2:39 PM EST - 7 months ago

The Law Offices of Frank R. Cruz Announces Investigation of Cytokinetics, Incorporated (CYTK) on Behalf of Investors

Jan 12, 2026, 12:45 PM EST - 8 months ago

Cytokinetics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:00 AM EST - 8 months ago

Cytokinetics Slides: Corporate presentation

Jan 5, 2026, 4:00 PM EST - 8 months ago

Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 19, 2025, 4:30 PM EST - 8 months ago

Cytokinetics Transcript: FDA Announcement

Dec 19, 2025, 4:30 PM EST - 8 months ago

Cytokinetics Press release: FDA Announcement

Dec 19, 2025, 4:08 PM EST - 8 months ago

US FDA approves Cytokinetics' heart disease drug

Dec 19, 2025, 4:00 PM EST - 8 months ago

Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

Dec 17, 2025, 7:30 AM EST - 9 months ago

Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy

Dec 12, 2025, 8:42 AM EST - 9 months ago

Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy

Nov 17, 2025, 9:30 AM EST - 10 months ago

Cytokinetics Transcript: Jefferies London Healthcare Conference 2025

Nov 17, 2025, 8:10 AM EST - 10 months ago

Cytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy

Quantumup Sep. 11 at 11:42 AM

0 · Reply

biochirp Sep. 9 at 1:38 AM

$CYTK should be 85+

0 · Reply

BiotechButterflies Sep. 8 at 7:53 PM

2 · Reply

SM07 Sep. 8 at 1:57 PM

$CYTK Usual morning pump followed by the afternoon dump

0 · Reply

forprofit12 Sep. 8 at 1:28 PM

$CYTK near term buyout possible. All the best

0 · Reply

biochirp Sep. 7 at 4:00 PM

$CYTK 3 CV drug failures the past couple weeks, is it time?

0 · Reply

Quantumup Sep. 1 at 10:11 AM

0 · Reply

buddyopalosam Aug. 31 at 4:46 PM

$CYTK ok i am out. This seems like. Its headed to tne 50's.

0 · Reply

JuniorTrader83 Aug. 31 at 4:29 PM

$CYTK buyers incoming 🚀

1 · Reply

macrossluvsrobotech Aug. 31 at 3:29 PM

0 · Reply

Floridaorange Aug. 31 at 2:26 PM

$CYTK for those who hunt asymmetric late-stage biotech NGEN — is worth putting on the research list. FDA-aligned registrational Phase 3 in chronic cervical SCI begins screening in September. ~$61M cash at Q2, runway through expected H1’28 topline. Phase 2 signal now supplemented by independent blinded biomechanical evidence. Tiny company attempting something with essentially no pharmacologic precedent in chronic SCI. High clinical risk, obviously—but the asymmetry is why it’s interesting. ✌️

0 · Reply

buddyopalosam Aug. 31 at 1:42 PM

$CYTK lol dumb

0 · Reply

DonCorleone77 Aug. 31 at 9:54 AM

$CYTK Cytokinetics announces results from ACACIA-HCM, MAPLE-HCM Cytokinetics announced that additional results from ACACIA-HCM and MAPLE-HCM were presented in a Late Breaking Clinical Session at the European Society of Cardiology, ESC, Congress 2026 in Munich, Germany and simultaneously published in Circulation and the Journal of the American College of Cardiology: Heart Failure, respectively. Key highlights: Additional Results from ACACIA-HCM Demonstrate Improvements in Cardiac Structure and Diastolic Function in Patients with Non-Obstructive HCM; New Analysis of MAPLE-HCM Finds Aficamten Outperformed Metoprolol Across Pre-Trial Treatment Groups in Patients with Obstructive HCM

0 · Reply

Invescent Aug. 31 at 5:42 AM

CATALYST WATCH — MONDAY $PTGX — FDA APPROVAL MIMRYLO approved for polycythemia vera. News released after Friday's close. Strongest weekend catalyst. $QNRX — PHASE 2/3 DATA Positive interim results. Primary endpoint p=0.0087. Closed $6.12 Friday. High volume. Financing/dilution risk. $NVAX— REGULATORY CATALYST Closed $9.26. XFG-adapted Nuvaxovid approvals announced for the U.S., EU and Japan for the 2026–27 season. $CYTK — PHASE 3 DATA Additional ACACIA-HCM and MAPLE-HCM results presented Saturday. MONDAY WATCHLIST 1. $PTGX — strongest catalyst 2. $QNRX — small-cap momentum 3. $NVAX — sub-$10 regulatory play 4. $CYTK — fresh weekend clinical data Watch the open

0 · Reply

buddyopalosam Aug. 30 at 10:02 PM

$CYTK someone gonna come asking for a deal here. Blum needs to sell for 18 to 20B. Deal is to be had here.

0 · Reply

Fedrano175 Aug. 29 at 1:46 PM

$CYTK not so foode...

0 · Reply

Jack_Danielss Aug. 29 at 10:09 AM

$CYTK Friday’s data also showed that in patients who stayed on Myqorzo for 72 weeks — about a year and four months — the placebo-adjusted change in KCCQ-CSS score widened to 7.0 points. And when patients stopped taking the drug for a month, their average KCCQ-CSS score dropped to match that of the placebo group.

0 · Reply

Jack_Danielss Aug. 29 at 10:03 AM

$CYTK At week 36, you have a three-point difference that is statistically significant, but then you have week 24, and week 48, and the weeks after … you have as high as seven points and as low as 4.5 to five points, which is a very sizable change,” Masri said. “Couple it with everything else going in the right direction, I think it’s a minor issue that at one time point you had less than a five-point change in KCCQ,” he added. Overreaction this will go back to $80+ BEST in class results

0 · Reply

Daniech0514 Aug. 28 at 6:38 PM

$CYTK https://www.tctmd.com/news/aficamten-wins-nonobstructive-hypertrophic-cardiomyopathy-acacia-hcm Contrary to what others have posted P vO2 is a hard metric to move and patients see improvement with as little as .4-.5 movement. Maybe lxrx drug will do better but final data us not out yet. https://www.hcplive.com/view/acacia-hcm-aficamten-beats-placebo-in-non-obstructive-hypertrophic-cardiomyopathy

0 · Reply

notreload_ai Aug. 28 at 4:49 PM

$CYTK Aficamten improved symptoms and exercise capacity in nHCM, yet the small effect sizes and higher heart-failure events left little new upside. https://notreload.xyz/xy/modest-gains-and-extra-safety-flags-sink-cytk-after-esc-data/

0 · Reply

buddyopalosam Aug. 28 at 3:29 PM

$CYTK garbage

0 · Reply

stefano62 Aug. 28 at 2:49 PM

$LXRX It seems that $CYTK will not submitt their NDA to FDA till Q4. This because they want to be sure to correctly fill the package with data relevant to the safety concerns. Indeed as #macrossluvsrobotech explained the mechanism of their drug are some side effects to be taken under control. While Sotaglifozin does not have those side effects, so if approved very probably $LXRX will have only few months delay to approach the HCM market

1 · Reply

Market Cap	9.18B
Revenue (ttm)	88.04M
Net Income (ttm)	-784.96M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-891.59%
Debt to Equity Ratio	-1.59

Volume	1,721,500
Avg Vol	1,817,870
Day's Range	N/A - N/A
Shares Out	124.43M
Stochastic %K	60%
Beta	0.36
Analysts	Strong Sell
Price Target	$108.52